Therapy Areas: Autoimmune
Forte Biosciences Names Brun to Board of Directors
16 November 2022 - - Dr. Scott Brun, M.D. has been appointed to US-based biopharmaceutical company Forte Biosciences, Inc's (NASDAQ: FBRX) board of directors, the company said.

Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics.

Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures.

In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organization responsible for the development of AbbVie's portfolio of early and late-stage clinical preregistration pipeline compounds as well as marketed compounds across a range of therapeutic areas. Dr Brun received his M.D. at The Johns Hopkins University School of Medicine.

Forte Biosciences, Inc. is a biopharmaceutical company and the lead product, FB-102, is a proprietary molecule with potentially broad autoimmune applications.